OncoSec Medical Incorporated · OTC:ONCSQ

OncoSec Medical — Investor Presentation (May 2020)

17 slides from OncoSec Medical's investor presentation, May 2020

  1. Slide 1: Powerful, Tumor-agnostic Immunotherapy Treatment

    Powerful, Tumor-agnostic Immunotherapy Treatment VLA: INTRODUCING THE NEW PITCH DECK VISCERAL LESION APPLICATOR 2019 1

  2. Slide 2: OncoSec’s Current Immunotherapy Platform

    OncoSec’s With our current applicator, we’ve seen systemic responses in both the treated Current and untreated tumors after applying our Immunotherapy therapies to cutaneous and subcutaneous tumors. Platform Many tumors, “especially cold Using the tumor as a gateway to Our current proprietary tumors

  3. Slide 3: What TAVO, Combined with CPIs, is Capable Of

    CASE STUDY Regression of untreated What TAVO, Combined mediastinal node and parenchymal lung with CPIs, is Capable Of metastases BASELINE TREATED LESION 12 RESPONSE: TUMOR FLARE, WEEKS NECROSIS REGRESSION OF ALL LESIONS 24 INCLUDING UNTREATED VISCERAL LESIONS IN LUNGS WEEKS AND DISTAL LYMPH NODES 3

  4. Slide 4: Urgent Treatment Options for Patients with Visceral Lesions

    TODAY, PRACTITIONERS NEED Urgent Treatment Options for Patients with Visceral Lesions LIVER GASTROINTESTINAL LUNG CANCER CANCER CANCER 42k 42K+ patients were diagnosed with liver 55k 55K+ patients were diagnosed with pancreatic cancer in 2018 2M 2M patients were diagnosed with lung cancer in 2018 ca

  5. Slide 5: Delivers the Same Powerful Therapy to Visceral Lesions

    PRACTITIONERS HAVE ASKED US TO DEVELOP A DEVICE THAT Delivers the Same Powerful Therapy to Visceral Lesions Tumors located inside the body, including gastrointestinal (GI) tumors, pancreatic tumors, and liver (e.g. HCC) tumors have unique challenges: OFTEN DIAGNOSED LATE CURRENT OPTIONS TO CHANGE WH

  6. Slide 6: The Power of TAVO for Visceral Lesions

    The Power of INTRODUCING THE VLA: Visceral Lesion Applicator TAVO for Visceral Lesions Based on encouraging and consistent data and a clear unmet demand, we Flexible catheter- A more rigid trocar-based designed a platform based applicator applicator to reach visceral lesions. CAN BE USED WITH Endosc

  7. Slide 7: Developing the Next Generation

    Developing the Next Generation COLOCALIZED Device INJECTION PORT 1.9MM DIA. The same powerful TAVO DISTAL END applicator miniaturized to reach visceral lesions DRUG DELIVERY PORT (SINGLE PROPRIETARY EXPANSION DESIGN NEEDLE) The expanded spacing of the electrodes is critical to achieve a higher rate

  8. Slide 8: The Flexible Catheter Applicator

    The Flexible Catheter Applicator The catheter-based applicator includes a flexible body that, with a diameter of 1.9mm, is sized for passage through currently available endoscopes, cystoscopes, and bronchoscopes. 1 2 3 NAVIGATE TO THE ENTERS THE ORGAN BY NEEDLE AND ELECTRODES ORGAN / LOCATION PUNCHI

  9. Slide 9: Rigid Trocar-based Applicator

    Rigid Trocar-based Applicator The trocar-based applicator accesses a visceral tumor using a minimally invasive transcutaneous approach under CT or ultrasound guidance. 1 2 3 ENTERS THE ORGAN NEEDLE AND ELECTROPORATION ELECTRODES EXPANDED OCCURS THERAPEUTIC AGENT CELL MEMBRANES BECOME ADMINISTERED PO

  10. Slide 10: Several live, large animal studies have been performed with the VLA

    APPLICATOR DEVELOPMENT STATUS Several live, large animal studies have been performed with the VLA Design control Phase I complete. Molded component design, material selection in process. Product design evaluation in process. Preclinical prototypes of both rigid trocar- Estimated based and flexible c

  11. Slide 11: The New Low Voltage Apollo Generator

    The New Low Voltage Apollo Generator will be used with Increased Lower voltage with longer duration pulses the Visceral Lesion Transfection Efficiency results in improved expression Applicators PRE-CLINICAL CLINICAL GENERATOR IS GENERATOR COMPLETE BUILT In use by Oncosec In software development and

  12. Slide 12: TRACE Technology Built In

    TRACE TISSUE-BASED REAL-TIME Technology TRACE ADAPTIVE CONTROL Built In E L E C T R O P O R AT I O N THE NEWEST GENERATOR COMES WITH THE ABILITY TO USE TRACE TECHNOLOGY BENEFIT = MORE CONTROL Different Cells Types Different Tumors Have Work Differently Different Reactions Generator receives informat

  13. Slide 13: A Focus on Safety Features

    A Focus GENERATOR APPLICATOR on Safety Always The Always Features Right Current Deployed Safely Continuous feedback system Embedded and deployable monitors electrodes within applicator to Throughout development we’ve energy delivery prevent accidental needle sticks been hyper-focused on the safety a

  14. Slide 14: VLA delivering immunotherapy alongside ablation, chemo and TACE

    THE VLA IS ABLE TO DELIVER TARGETED IMMUNOTHERAPIES, WHICH HAVE THE POTENTIAL TO ACT IN CONCERT WITH EXISTING THERAPIES TO DRIVE ENHANCED RESPONSES IN IMMUNOLOGICALLY COLD TUMORS. ABLATION CHEMO TACE SYSTEMIC IMMUNOTHERAPY 14

  15. Slide 15: Key Milestones in Our Path to Market

    POTENTIAL DUAL REGULATORY PATHWAY PROVIDES FOR BENEFITS NEARER TERM APPROVAL OF STANDALONE DEVICE (VLA) AND CONCURRENT COMBINATION IND WITH VLA + Faster pathway to clinic TAVO (OR NEXT-GEN PLASMID) Faster marketing authorization = Quicker time to revenue Parallel device filing will be used in order

  16. Slide 16: Established Biotech Leaders With a Track Record of Success

    Established Biotech Leaders BOARD OF DIRECTORS WITH A TRACK RECORD OF SUCCESS Daniel J. O’Connor Chief Executive Officer & Director Margaret R. Dalesandro, Ph.D., Chair Robert E. Ward, Director H. Kim Lyerly, Ph.D. Director MANAGEMENT Chao (Frank) Zhou, Director Kevin R. Smith, Director Keir Loiacon

  17. Slide 17: Thank You

    Thank You Keir Loiacono 914.329.9071 kloiacono@oncosec.com 17

OncoSec Medical — Investor Presentation (May 2020) on 6ix